Briacell Therap (NASDAQ:BCTX) Sees Significant Decline in Short Interest

Briacell Therap (NASDAQ:BCTX) was the recipient of a large decrease in short interest during the month of June. As of June 15th, there was short interest totaling 377,009 shares, a decrease of 56.6% from the May 31st total of 867,761 shares. Based on an average daily volume of 250,931 shares, the days-to-cover ratio is currently 1.5 days. Currently, 4.4% of the shares of the company are short sold.

Briacell Therap Stock Performance

BCTX traded up $0.18 on Tuesday, hitting $3.28. 85,101 shares of the company were exchanged, compared to its average volume of 346,464. Briacell Therap has a fifty-two week low of $2.60 and a fifty-two week high of $31.10. The firm has a market capitalization of $28.54 million, a P/E ratio of -0.41 and a beta of 1.21. The business’s fifty day moving average is $3.50 and its 200 day moving average is $4.69.

Briacell Therap (NASDAQ:BCTX) last released its quarterly earnings results on Tuesday, June 9th. The company reported ($0.99) earnings per share for the quarter.

Institutional Trading of Briacell Therap

A hedge fund recently bought a new stake in Briacell Therap stock. Flagship Harbor Advisors LLC bought a new stake in shares of Briacell Therap (NASDAQ:BCTX) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 4,000 shares of the company’s stock, valued at approximately $28,000. Flagship Harbor Advisors LLC owned about 0.21% of Briacell Therap as of its most recent filing with the SEC. Hedge funds and other institutional investors own 15.42% of the company’s stock.

Analysts Set New Price Targets

BCTX has been the subject of a number of recent research reports. Wall Street Zen raised Briacell Therap from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Briacell Therap in a report on Monday, April 20th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.